tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Pulse Biosciences Publishes Promising Thyroid Study Results

Story Highlights
  • Pulse Biosciences published early data on its CellFX nsPFA system for benign thyroid nodules.
  • The study showed up to 93% nodule size reduction, highlighting safety and rapid symptom relief.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Pulse Biosciences Publishes Promising Thyroid Study Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Pulse Biosciences ( (PLSE) ).

On August 26, 2025, Pulse Biosciences announced the publication of early data from a clinical study on its CellFX nsPFA Percutaneous Electrode System for treating benign thyroid nodules in the journal Thyroid. Conducted by Professor Stefano Spiezia in Naples, Italy, the study demonstrated the system’s effectiveness, showing up to a 93% reduction in nodule size within a year and significant symptom relief. The results highlight the system’s advantages over traditional methods, such as thyroidectomy, with a favorable safety profile and rapid symptom reduction, positioning Pulse Biosciences as a leader in innovative thyroid nodule treatment.

The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.

Spark’s Take on PLSE Stock

According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.

Pulse Biosciences receives a low overall score due to persistent financial challenges such as continuous losses and cash burn. While technical indicators show some positive momentum, the valuation remains unattractive due to negative earnings. The earnings call provided a balanced view with notable advancements in technology and strengthened finances, but increased operational costs remain a concern. The CFO appointment is a positive strategic move but does not significantly affect the overall score.

To see Spark’s full report on PLSE stock, click here.

More about Pulse Biosciences

Pulse Biosciences is a novel bioelectric medicine company focused on health innovation, aiming to improve patient quality of life through its proprietary CellFX nsPFA technology. This technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is developing this technology for use in treating atrial fibrillation and other markets where it could significantly impact healthcare.

Average Trading Volume: 171,049

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.11B

For a thorough assessment of PLSE stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1